Antimicrobial resistance

The burden of AMR in Thailand has been estimated in 2010 to result in 3.24 million days of hospitalization and 38 481 deaths per annum, and to cost 0.6% of national GDP. The Thai National Strategic Plan on Antimicrobial Resistance (2017–2021), which aims to reduce morbidity, mortality and the economic impact of AMR, was finalized and endorsed by the Cabinet in late 2016. The plan sets targets for a 50% reduction in AMR morbidity; 20% and 30% reductions in antimicrobial use in human and animal respectively, and a 20% increase in public knowledge about AMR, including awareness of appropriate use of antimicrobials. The CCS programme aims to support execution of the plan, including arrangements for monitoring and evaluation, and to strengthen evidence-based implementation.

Antimicrobial Resistance

Key issues

  • Ensuring an integrated ‘One Health’ approach, including coordination within the human health sector, as well as with agriculture and environment sectors
  • Strengthening and integrating AMR surveillance and monitoring systems
  • Establishing and ensuring compliance with policies for the optimal use of antibiotics in and outside of health-care settings
  • Identifying and addressing knowledge gaps to guide AMR policies and programmes
  • Limited human resources

Focus areas

  • Strengthen individual and institutional capacities (including capacity to generate evidence) for effective NSP-AMR implementation
  • Identify and disseminate evidence to relevant NSP-AMR implementing agencies for effective implementation
  • Strengthen existing M&E platforms and develop other essential implementation platforms where needed

CCS deliverables

  • Quality-assured and representative laboratory and epidemiological surveillance for resistant organisms that is regularly shared with AMR stakeholders
  • Improved systems for monitoring antibiotic consumption in humans and animals, with effective dissemination of information to human and animal constituencies
  • Strengthened capacity for generation of evidence to inform AMR policy
  • Sustainable platforms for M&E of AMR programme implementation
  • Baseline, mid-term and final reports produced based on parameters defined by the AMR component of the WHO/ IHR ‘Joint External Evaluation’ tool


Thailand reduces AMR-related morbidity and mortality as per defined national targets

Lead agencies

Food and Drug Administration, International Health Policy Programme

WHO will contribute and add value by:

  • Providing direct financial and technical input for programme implementation, including normative support, technical consultations and generation of evidence to inform policy
  • Supporting governance of the AMR programme
  • Facilitating engagement with AMR stakeholders, including FAO, other concerned UN agencies and NGOs.
  • Supporting Thailand’s work on AMR beyond its borders, including supporting the role of WHO Collaborating Centres on AMR in Thailand